274 related articles for article (PubMed ID: 28208174)
1. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Basch E; Dueck AC; Rogak LJ; Minasian LM; Kelly WK; O'Mara AM; Denicoff AM; Seisler D; Atherton PJ; Paskett E; Carey L; Dickler M; Heist RS; Himelstein A; Rugo HS; Sikov WM; Socinski MA; Venook AP; Weckstein DJ; Lake DE; Biggs DD; Freedman RA; Kuzma C; Kirshner JJ; Schrag D
JAMA Oncol; 2017 Aug; 3(8):1043-1050. PubMed ID: 28208174
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):409-418. PubMed ID: 28463161
[TBL] [Abstract][Full Text] [Related]
3. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
[TBL] [Abstract][Full Text] [Related]
5. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
[TBL] [Abstract][Full Text] [Related]
6. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
[TBL] [Abstract][Full Text] [Related]
7. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.
Basch E; Rogak LJ; Dueck AC
Clin Ther; 2016 Apr; 38(4):821-30. PubMed ID: 27045992
[TBL] [Abstract][Full Text] [Related]
8. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Basch E; Reeve BB; Mitchell SA; Clauser SB; Minasian LM; Dueck AC; Mendoza TR; Hay J; Atkinson TM; Abernethy AP; Bruner DW; Cleeland CS; Sloan JA; Chilukuri R; Baumgartner P; Denicoff A; St Germain D; O'Mara AM; Chen A; Kelaghan J; Bennett AV; Sit L; Rogak L; Barz A; Paul DB; Schrag D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265940
[TBL] [Abstract][Full Text] [Related]
9. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bennett AV; Dueck AC; Mitchell SA; Mendoza TR; Reeve BB; Atkinson TM; Castro KM; Denicoff A; Rogak LJ; Harness JK; Bearden JD; Bryant D; Siegel RD; Schrag D; Basch E;
Health Qual Life Outcomes; 2016 Feb; 14():24. PubMed ID: 26892667
[TBL] [Abstract][Full Text] [Related]
10. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
Veitch ZW; Shepshelovich D; Gallagher C; Wang L; Abdul Razak AR; Spreafico A; Bedard PL; Siu LL; Minasian L; Hansen AR
J Natl Cancer Inst; 2021 Aug; 113(8):980-988. PubMed ID: 33616650
[TBL] [Abstract][Full Text] [Related]
11. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.
Atkinson TM; Ryan SJ; Bennett AV; Stover AM; Saracino RM; Rogak LJ; Jewell ST; Matsoukas K; Li Y; Basch E
Support Care Cancer; 2016 Aug; 24(8):3669-76. PubMed ID: 27260018
[TBL] [Abstract][Full Text] [Related]
12. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Kluetz PG; Chingos DT; Basch EM; Mitchell SA
Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
[TBL] [Abstract][Full Text] [Related]
13. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Hay JL; Atkinson TM; Reeve BB; Mitchell SA; Mendoza TR; Willis G; Minasian LM; Clauser SB; Denicoff A; O'Mara A; Chen A; Bennett AV; Paul DB; Gagne J; Rogak L; Sit L; Viswanath V; Schrag D; Basch E;
Qual Life Res; 2014 Feb; 23(1):257-69. PubMed ID: 23868457
[TBL] [Abstract][Full Text] [Related]
14. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
[TBL] [Abstract][Full Text] [Related]
16. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
[TBL] [Abstract][Full Text] [Related]
17. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
[TBL] [Abstract][Full Text] [Related]
18. Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
Shepshelovich D; McDonald K; Spreafico A; Razak ARA; Bedard PL; Siu LL; Minasian L; Hansen AR
Oncologist; 2019 Apr; 24(4):e146-e148. PubMed ID: 30728278
[TBL] [Abstract][Full Text] [Related]
19. Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience.
Albaba H; Barnes TA; Veitch Z; Brown MC; Shakik S; Su S; Naik H; Wang T; Liang M; Perez-Cosio A; Eng L; Mittmann N; Xu W; Howell D; Liu G
Oncologist; 2019 Nov; 24(11):e1219-e1227. PubMed ID: 31409744
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.
Basch E; Wood WA; Schrag D; Sima CS; Shaw M; Rogak LJ; Kris MG; Shouery M; Bennett A; Atkinson T; Pietanza MC
Clin Trials; 2016 Jun; 13(3):331-7. PubMed ID: 26542025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
